Link between IDRA and PCYC? Perhaps the reason Baker Bros are interested?
Interesting that Baker Bros was one of the earliest and largest holders of Pharmacyclics, and now they appear to be doing the same with Idera. PCYC's superstar Imbruvica targets Mantle Cell Lymphoma, and Idera's lead candidate IMO-8400 targets Lymphoma as well. Perhaps, just perhaps, Baker Bros sees IDRA as the next PCYC. Looks like trial activity in this area for Idera will be spinning up shortly. Thoughts from other Idera longs?
I hate to rain on everyone's party, but the Baker Brothers are known for being pumpers and dumpers. They specialize in buying millions of shares of small biotechs, announcing they bought the shares, and selling them quickly after the run up.
They were one of the top hedge funds last years (15% return) and none of their picks were held very long. They made massive profits by selling into the rallies. They are not investors, they are profiteers.
I would very much be willing to bet my hat they have gone round trip in IDRA, which explains the ride to 3, and the abrupt journey back to 1.87.
Of course, you don't have to take my word for it. You could call IDRA shareholder relations and ask directly.
For any newbies out there, this one is a dead giveaway. I might use the name 'longtimeidralong" if I had put most of my money into Idera a long time ago. But then I would have had to sell my computer on Craigslist by now and I wouldn't be typing this. So it's an alias for an agenda he's pushing today with whatever nonsense he can make up.
False. Baker Bros is smart money and will be in a company for as long as they like their prospects. They bought 4.5m shares IDRA at or around the offering @$1.55 then bought another 1.38m shares on the next dip @ $1.65 or so. And they are not alone, 4-5 other funds bought in as well at the same time. Odds are this stock will be much, much higher before they sell!
Baker Bros have a good history in evaluating potential pharma companies , there staff have excellent reputation in evaluating science , and not speculation , their latest investments in IDERA , and further increases in position have defenitly a valid reason
I agree, Baker holding IDRA is great, adding last quarter even sweeter, but the common tread of Baker, PCYC, IDRA and Lymphoma raised eyebrows. Something special about IDRA I bet. Trial kicks off soon.